KDKatherine Dick

Katherine Dick

*This is an algorithmically generated author record based on publicly available information.

Katherine Dick has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Mendelian randomization: estimation of inpatient hospital costs attributable to obesity

    by Katherine Dick, John E. Schneider, Andrew Briggs, Pascal Lecomte, Stephane A. Regnier, Michael Lean

    Background Mendelian Randomization is a type of instrumental variable (IV) analysis that uses inherited genetic variants as instruments to estimate causal effects attributable to genetic factors. This study aims to estimate the impact of obesity on annual inpatient healthcare costs in the UK using linked data from the UK Biobank and Hospital Episode Statistics (HES). Methods UK Biobank data for 482,127 subjects was linked with HES inpatient admission records, and costs were assigned to episodes of care. A two-stage least squares (TSLS) IV model and a TSLS two-part cost model were compared to a naive regression of inpatient healthcare costs on body mass index (BMI). Results The naive analysis of annual cost on continuous BMI predicted an annual cost of 21.61 pound [95% CI 20.33 pound - 22.89] pound greater cost per unit increase in BMI. The TSLS IV model predicted an annual cost of 14.36 pound [95% CI 0.31 pound - 28.42] pound greater cost per unit increase in BMI. Modelled with a binary obesity variable, the naive analysis predicted that obese subjects incurred 205.53 pound [95% CI 191.45 pound - 219.60] pound greater costs than non-obese subjects. The TSLS model predicted a cost 201.58 pound [95% CI 4.32 pound - 398.84] pound greater for obese subjects compared to non-obese subjects. Conclusions The IV models provide evidence for a causal relationship between obesity and higher inpatient healthcare costs. Compared to the naive models, the binary IV model found a slightly smaller marginal effect of obesity, and the continuous IV model found a slightly smaller marginal effect of a single unit increase in BMI.


  • Open Access

    Application of a Mapping Function to Estimate Utilities for Ragweed Allergy Immunotherapy Trials

    by Katherine Dick, Andrew Briggs, Henrik Brandi

    Background Ragweed pollen sensitivity is a common cause of allergic rhinitis (AR) worldwide. AR symptoms include itchy and runny eyes, sneezing, blocked nose, impaired sleep and social and emotional problems, which can have a significant impact on quality of life. Objective The objective of this analysis was to estimate utilities for two pooled standardised quality (SQ) ragweed sublingual immunotherapy (SLIT) tablet trials by applying a previously developed mapping algorithm. This study validated the algorithm and extended its application to ragweed seasonal allergy trials. The mapping algorithm relates disease-specific quality-of-life scores to preference-based utilities that may be used to calculate quality-adjusted life-years (QALYs) in cost-effectiveness studies. Methods A mapping algorithm based on a grass pollen allergy immunotherapy trial, GT-08 (EudraCT no. 2004-000083-27) was applied to pooled data from two ragweed pollen immunotherapy trials, P05233 (EudraCT 2008-003863-38) and P05234 (EudraCT 2008-003864-20) to generate EuroQoL 5-Dimensions, 3-Levels (EQ-5D-3L) utilities from Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) data. Results The mean utility difference between the SQ ragweed SLIT tablet and placebo was 0.025 [95% confidence interval (CI) 0.011–0.038]. The SQ ragweed SLIT tablet showed an incremental quality-adjusted life-days (QALDs) benefit of 1.900 (95% CI 0.835–2.916) over 75 days. Conclusions Application of a previously developed mapping function allowed for the calculation of QALDs associated with the SQ ragweed SLIT tablet. The results showed a QALD benefit of the SQ ragweed SLIT tablet in P05233 and P05234 trials in the treatment of ragweed pollen-induced AR.


  • Open Access

    A quality-of-life mapping function developed from a grass pollen sublingual immunotherapy trial to a tree pollen sublingual immunotherapy trial

    by Katherine Dick, Andrew Briggs, Robert Ohsfeldt, Tobias Sydendal Grand, Sarah Buchs

    Aims: Allergic rhinitis is caused by sensitivity to environmental allergens that can significantly impact quality-of-life. The objective of this analysis was to estimate health state utilities and quality-adjusted life days (QALDs) for a tree allergy immunotherapy trial, TT-04 (EudraCT No.2015-004821-15). Health-state utilities are a measure of patient preference for health states and are necessary to derive QALDs for cost-utility analysis. Preference-based utilities were not collected in the TT-04 trial, so a mapping algorithm was developed based on a similar grass allergy immunotherapy trial, GT-08 (EudraCT No. 2004-000083-27), to estimate utilities. Methods: A two-part model was developed to predict utilities for the GT-08 trial and applied to the TT-04 trial to estimate the difference in mean utility and QALDs between SQ tree sublingual immunotherapy (SLIT)-tablet and placebo. Results: Mean utility difference between SQ tree SLIT-tablet and placebo was 0.030 [95% CI = 0.015–0.046] during the birch pollen season (BPS), 0.019 [95% CI = 0.007–0.030] during the tree pollen season (TPS) and 0.018 [95% CI = 0.007–0.030] during the full trial. The treatment showed a QALD benefit of 1.26 [95% CI = 0.619–1.917] during the BPS, 1.90 [95% CI = 0.692–3.047] during the TPS, and 2.47 [95% CI = 0.930–4.101] during the full trial. Limitations: The generalizability of this algorithm is limited to allergy trials containing the same covariates as those present in the model. The analysis also assumes that grass and tree pollen allergy have the same relationship with EQ5D utilities, which is supported by the fact that both grass and tree pollen induce similar symptoms. Conclusions: Application of the mapping function enabled the calculation of QALDs associated with the treatment, with the caveat that data were extrapolated from grass seasonal allergy to tree seasonal allergy. The results showed a significant QALD benefit of the treatment over placebo in treatment of tree pollen-induced rhinoconjunctivitis.